HUTCHMED has announced the publication of Phase III ESLIM-01 results in The Lancet Haematology.
The publication revealed that the treatment had a durable response rate of 48.4% compared to 0% with the placebo. Presentations at EHA highlighted subgroup analyses that showed consistent benefits regardless of prior treatments.
